FOLH1 and prostate cancer: As reported by the phase III VISION trial [22], radioligand therapy with 177Lu-PSMA-617 was able to prolong progression-free survival (PFS) and overall survival (OS) when added to standard care in patients with advanced metastatic castration-resistant prostate cancer.